Abstracts Archive - Page 789 of 2607 - ACR Meeting Abstracts

Abstract Number: 1258 • ACR Convergence 2021
Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials
Kathryn Connelly¹, Jeevan Vettivel², Vera Golder², Rangi Kandane-Rathnayake² and Eric Morand³, ¹Monash University, Camberwell, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia
Background/Purpose: Randomised controlled trials (RCTs) in SLE typically adopt composite responder definitions as primary efficacy endpoints, however outcomes within individual organ domains are also important…
Abstract Number: 1259 • ACR Convergence 2021
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes
Kathryn Connelly¹, Rangi Kandane-Rathnayake¹, Alberta Hoi², Worawit Louthrenoo³, Laniyati Hamijoyo⁴, Jiacai Cho⁵, Aisha Lateef⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, C.S. Lau⁹, YI-HSING CHEN¹⁰, Sandra Navarra¹¹, Leonid Zamora¹¹, Zhanguo Li¹², Yuan An¹², Sargunan Sockalingam¹³, Yanjie Hao¹⁴, Zhuoli Zhang¹⁴, Madelynn Chan¹⁵, Yasuhiro Katsumata¹⁶, Masayoshi Harigai¹⁶, Shereen Oon¹⁷, Sang-Cheol Bae¹⁸, Sean O’Neill¹⁹, Kathryn Gibson¹⁹, Jun Kikuchi²⁰, B.M.D.B. Basnayake²¹, Tsutomu Takeuchi²², Kristine (Pek Ling) Ng²³, Fiona Goldblatt²⁴, Annie Law²⁵, Nicola Tugnet²⁶, Yoshiya Tanaka²⁷, Sunil Kumar²⁸, Michael Tee²⁹, Jin Yu Tan³⁰, Chetan Karyekar³¹, Mandana Nikpour³², Vera Golder¹ and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ⁴University of Padjadjaran, Bandung, Indonesia, ⁵National University Health System (NUHS), Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹³University of Malaya, Kuala Lumpur, Malaysia, ¹⁴Peking University First Hospital, Beijing, China (People's Republic), ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁷Melbourne Health, Parkville, Australia, ¹⁸Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁹Liverpool Hospital, Sydney, Australia, ²⁰Keio University School of Medicine, Tokyo, Japan, ²¹Teaching (General) Hospital, Kandy, Sri Lanka, ²²Div. Rheumatology, Keio University, Tokyo, Japan, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Flinders Medical Centre, Adelaide, Australia, ²⁵Singhealth, Singapore, Singapore, ²⁶Auckland District Health Board, Auckland, New Zealand, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸Counties Manukau Health, Auckland, New Zealand, ²⁹University of the Philippines, Quezon City, Philippines, ³⁰Janssen Asia Pacific, Singapore, Singapore, ³¹Janssen R&D, Spring House, PA, ³²University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ³³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: The SLE Responder Index (SRI) is a composite responder definition employed as a clinical trial endpoint in SLE. Despite its widespread adoption, recent discrepant…
Abstract Number: 1260 • ACR Convergence 2021
Factors That Impact Medication Adherence in Hospitalized Patients with Systemic Lupus Erythematosus
Prarthana Jain¹, Mithu Maheswaranathan², Holly Mitchell³ and Diane Kamen¹, ¹Medical University of South Carolina, Charleston, SC, ²Duke University School of Medicine, Durham, NC, ³Ralph H Johnson VA Medical Center, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by episodes of flares, often involving multiple organ systems. Medication nonadherence remains a significant problem,…
Abstract Number: 1261 • ACR Convergence 2021
The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
Sharzad Emamikia¹, Shereen Oon², Alvaro Gomez¹, Julius Lindblom¹, Alexander Borg¹, Yvonne Enman¹, Eric Morand³, David Grannas⁴, Ronald van Vollenhoven⁵, Mandana Nikpour⁶ and Ioannis Parodis⁷, ¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Department of Rheumatology, St Vincent's Hospital, Fitzroy, Australia, ³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia, ⁴Divison of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
Background/Purpose: Health-related quality of life (HRQoL) is considered one of the most important outcomes in clinical trials of systemic lupus erythematosus (SLE), along with reduction…
Abstract Number: 1262 • ACR Convergence 2021
Fish Oil Supplementation and Pro-inflammatory and Pro-Resolving Lipid Mediators in Patients with and Without Systemic Lupus Erythematosus
May Choi¹, Nancy Cook², Emma Stevens², Natalya Gomelskaya², Gregory Kotler³, JoAnn Manson³, Jessica Lasky-Su², Raju Tatituri², Samia Mora², I-Min Lee³, Charles Serhan² and Karen Costenbader⁴, ¹Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Omega-3 fatty acid-derived “specialized pro-resolving mediators” (SPM) are low-abundance lipid mediators (LM) central to inflammation resolution. In this cross-sectional study, we investigated whether fish…
Abstract Number: 1263 • ACR Convergence 2021
Treatment of Pediatric Lupus Is Associated with Significant Re-Organization of B Cell Chromatin
Joyce Hui-Yuen¹, Kaiyu Jiang², Susan Malkiel³, Betty Diamond³ and James Jarvis⁴, ¹North Shore LIJ Health System, Great Neck, NY, ²University at Buffalo, Buffalo, NY, ³Northwell Health, Manhasset, NY, ⁴University at Buffalo Jacobs School of Medicine, Buffalo, NY
Background/Purpose: Systemic lupus erythematosus (SLE) may be triggered by gene-environment interactions. Data remain scarce on how epigenetic variance contributes to disease risk in pediatric SLE…
Abstract Number: 1264 • ACR Convergence 2021
Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study
James Sullivan¹ and Emily Littlejohn², ¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated…
Abstract Number: 1265 • ACR Convergence 2021
Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Osteoporosis with fractures is consistently one of the top three items in the SLICC/ACR Damage Index in cohort studies internationally. As vitamin D insufficiency…
Abstract Number: 1266 • ACR Convergence 2021
Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus
Meghan Nelson¹, Lori Ponder², Sinclair Gibson³, D. Sofia Villacis- Nunez¹, Lai Hin Kimi Chan³, Lakshmi Moorthy⁴ and Sampath Prahalad⁵, ¹Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Children’s Healthcare of Atlanta, Atlanta, GA, ⁴Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Childhood systemic lupus erythematosus (cSLE) is a life-long disease with significant morbidity and mortality, and with associated significant impact on health-related quality of life…
Abstract Number: 1267 • ACR Convergence 2021
Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
Sarah Lieber¹, Iris Navarro-Milln², Musarrat Nahid², Mangala Rajan², Sebastian Sattui¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Emergency department (ED) utilization is associated with worse quality of care and health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE). While frailty…
Abstract Number: 1268 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods
Melissa Fazzari¹, Marta Guerra², Jane Salmon² and Mimi Kim³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Hospital for Special Surgery, New York, NY, ³Albert Einstein College of Medicine, Larchmont, NY
Background/Purpose: Nearly 20% of pregnancies in patients with Systemic lupus erythematosus (SLE) result in an adverse pregnancy outcome (APO); early identification of women with SLE…
Abstract Number: 1269 • ACR Convergence 2021
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Shannon Grabich¹, Eilleen Farrelly², Robert Ortmann³, Michael Pollack⁴ and Sandra Sze-jung Wu⁴, ¹Xcenda, Durham, NC, ²Xcenda, Carrollton, TX, ³AstraZeneca, Greenwood, IN, ⁴AstraZeneca, Wilmington, DE
Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…
Abstract Number: 1270 • ACR Convergence 2021
Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus
Shirley Huang¹, Amy Guisinger², Carlyne Averell¹ and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), occurring in approximately 40% of SLE patients (pts) and often resulting in…
Abstract Number: 1271 • ACR Convergence 2021
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
Shirley Huang¹, Amy Guisinger² and Christopher Bell¹, ¹GlaxoSmithKline, Research Triangle Park, NC, ²US Value, Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Approximately 40% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN), of whom up to 20% may progress to end-stage kidney disease…
Abstract Number: 1272 • ACR Convergence 2021
Characterizing Patient and Physician Perceptions of Systemic Lupus Erythematosus (SLE) Disease Burden Using Traditional Rheumatoid Arthritis Outcomes Measures
Christopher Bell¹, Shirley Huang¹, Meg Wang², Maral DerSarkissian², Mei Sheng Duh², Bhavna Dhillon³, Carlyne Averell¹, Bernie Rubin¹ and Daniel Wallace⁴, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Analysis Group, Boston, MA, ³United Rheumatology, Hauppauge, NY, ⁴Cedars-Sinai, Los Angeles, CA
Background/Purpose: SLE is a chronic, autoimmune disease affecting multiple organ systems, and characterized by fluctuating disease activity. Many SLE disease measures may be impractical for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].